• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Allogene Therapeutics Inc.

    5/9/25 5:49:01 PM ET
    $ALLO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Allogene Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    019770106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    019770106


    1Names of Reporting Persons

    David D. Chang, M.D., Ph.D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    8,129,904.00
    6Shared Voting Power

    2,913,196.00
    7Sole Dispositive Power

    8,129,904.00
    8Shared Dispositive Power

    2,913,196.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,043,100.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    019770106


    1Names of Reporting Persons

    Chang 2006 Family Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,201,108.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,201,108.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,201,108.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    019770106


    1Names of Reporting Persons

    JEC 2019 Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    856,044.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    856,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    856,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    019770106


    1Names of Reporting Persons

    RTC 2019 Trust
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    6Shared Voting Power

    856,044.00
    7Sole Dispositive Power

    8Shared Dispositive Power

    856,044.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    856,044.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Allogene Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    210 East Grand Avenue, South San Francisco, CA, 94080.
    Item 2. 
    (a)Name of person filing:

    David D. Chang, M.D., Ph.D. Chang 2006 Family Trust JEC 2019 Trust RTC 2019 Trust
    (b)Address or principal business office or, if none, residence:

    David D. Chang, M.D., Ph.D.: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 Chang 2006 Family Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 JEC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401 RTC 2019 Trust: 1755 Ocean Avenue, #803, Santa Monica, CA 90401
    (c)Citizenship:

    David D. Chang, M.D. Ph.D.: USA Chang 2006 Family Trust: California JEC 2019 Trust: California RTC 2019 Trust: California
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    019770106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Row 9 of Dr. Chang's cover page includes 5,319,786 shares of common stock issuable within 60 days of March 31, 2025 upon the exercise of stock options held by Dr. Chang, and also includes (a) 1,201,108 shares of common stock beneficially owned by the Chang 2006 Family Trust, of which Dr. Chang is co-trustee, (b) 856,044 shares of common stock beneficially owned by the JEC 2019 Trust, of which Dr. Chang is co-trustee and (c) 856,044 shares of common stock beneficially owned by the RTC 2019 Trust, of which Dr. Chang is co-trustee.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. This percentage is calculated based on 217,264,738 shares of common stock outstanding as of March 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-K filed on March 13, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    David D. Chang, M.D., Ph.D.
     
    Signature:/s/ David D. Chang
    Name/Title:David D. Chang, M.D., Ph.D.
    Date:05/09/2025
     
    Chang 2006 Family Trust
     
    Signature:/s/ David D. Chang
    Name/Title:By David D. Chang, M.D., Ph.D., Co-Trustee
    Date:05/09/2025
     
    JEC 2019 Trust
     
    Signature:/s/ David D. Chang
    Name/Title:By David D. Chang, M.D., Ph.D., Co-Trustee
    Date:05/09/2025
     
    RTC 2019 Trust
     
    Signature:/s/ David D. Chang
    Name/Title:By David D. Chang, M.D., Ph.D., Co-Trustee
    Date:05/09/2025
    Exhibit Information

    Joint Filing Agreement

    Get the next $ALLO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALLO

    DatePrice TargetRatingAnalyst
    5/14/2025Mkt Outperform → Mkt Perform
    Citizens JMP
    3/14/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    8/8/2024$13.00 → $11.00Outperform
    Oppenheimer
    5/31/2024$11.00Overweight
    Piper Sandler
    1/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    1/5/2024Buy → Neutral
    Guggenheim
    12/8/2023$7.00Buy
    Citigroup
    12/8/2023Buy
    Citigroup
    More analyst ratings